Blood mass spectrometry detects residual disease better than standard techniques in light-chain amyloidosis.
Dispenzieri A, Arendt B, Dasari S, Kohlhagen M, Kourelis T, Kumar SK, Leung N, Muchtar E, Buadi FK, Warsame R, Kyle RA, Lacy MQ, Dingli D, Kapoor P, Gonsalves WI, Go RS, Hayman SR, Hwa YL, Fonder A, Hobbs M, Jevremovic D, Lust JA, Zeldenrust S, Russell SJ, Rajkumar SV, Gertz MA, Murray D.
Dispenzieri A, et al.
Blood Cancer J. 2020 Feb 25;10(2):20. doi: 10.1038/s41408-020-0291-8.
Blood Cancer J. 2020.
PMID: 32098948
Free PMC article.